Illumina is trading lower today, experiencing mild pressure as it retreats from the 52-week high of $278.99 reached during the previous session.
The stock is seeing some profit-taking following a period of significant momentum, compounded by recent data showing that ETFs were net sellers of $41.5 million in shares as of September 25. This downward movement aligns with broader weakness in the diagnostics and research industry, as peer Qiagen is also trading lowe